These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37666718)

  • 21. Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects.
    Huang YW; Tsai CY; Tsai CW; Wang W; Zhang J; Qin A; Teng C; Song B; Wang MX
    Adv Ther; 2021 Sep; 38(9):4756-4770. PubMed ID: 34328630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
    Ascione A; De Luca M; Tartaglione MT; Lampasi F; Di Costanzo GG; Lanza AG; Picciotto FP; Marino-Marsilia G; Fontanella L; Leandro G
    Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.
    Rosen I; Kori M; Eshach Adiv O; Yerushalmi B; Zion N; Shaoul R
    World J Gastroenterol; 2013 Feb; 19(7):1098-103. PubMed ID: 23467199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin.
    Oze T; Hiramatsu N; Song C; Yakushijin T; Iio S; Doi Y; Oshita M; Hagiwara H; Mita E; Ito T; Inui Y; Hijioka T; Tamura S; Yoshihara H; Inoue A; Imai Y; Hayashi E; Kato M; Miyazaki M; Hosui A; Miyagi T; Yoshida Y; Tatsumi T; Kiso S; Kanto T; Kasahara A; Hayashi N; Takehara T
    J Gastroenterol; 2012 Mar; 47(3):334-42. PubMed ID: 22109353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
    Sulkowski M; Pol S; Mallolas J; Fainboim H; Cooper C; Slim J; Rivero A; Mak C; Thompson S; Howe AY; Wenning L; Sklar P; Wahl J; Greaves W;
    Lancet Infect Dis; 2013 Jul; 13(7):597-605. PubMed ID: 23768747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).
    Silva M; Poo J; Wagner F; Jackson M; Cutler D; Grace M; Bordens R; Cullen C; Harvey J; Laughlin M
    J Hepatol; 2006 Aug; 45(2):204-13. PubMed ID: 16780997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.
    Buti M; Sanchez-Avila F; Lurie Y; Stalgis C; Valdés A; Martell M; Esteban R
    Hepatology; 2002 Apr; 35(4):930-6. PubMed ID: 11915041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.
    McPhee F; Hernandez D; Zhou N; Yu F; Ueland J; Monikowski A; Chayama K; Toyota J; Izumi N; Yokosuka O; Kawada N; Osaki Y; Hughes EA; Watanabe H; Ishikawa H; Kumada H
    Antivir Ther; 2014; 19(5):479-90. PubMed ID: 24448487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.
    Muir AJ; Arora S; Everson G; Flisiak R; George J; Ghalib R; Gordon SC; Gray T; Greenbloom S; Hassanein T; Hillson J; Horga MA; Jacobson IM; Jeffers L; Kowdley KV; Lawitz E; Lueth S; Rodriguez-Torres M; Rustgi V; Shemanski L; Shiffman ML; Srinivasan S; Vargas HE; Vierling JM; Xu D; Lopez-Talavera JC; Zeuzem S;
    J Hepatol; 2014 Dec; 61(6):1238-46. PubMed ID: 25064437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.
    Wirth S; Ribes-Koninckx C; Calzado MA; Bortolotti F; Zancan L; Jara P; Shelton M; Kerkar N; Galoppo M; Pedreira A; Rodriguez-Baez N; Ciocca M; Lachaux A; Lacaille F; Lang T; Kullmer U; Huber WD; Gonzalez T; Pollack H; Alonso E; Broue P; Ramakrishna J; Neigut D; Valle-Segarra AD; Hunter B; Goodman Z; Xu CR; Zheng H; Noviello S; Sniukiene V; Brass C; Albrecht JK
    J Hepatol; 2010 Apr; 52(4):501-7. PubMed ID: 20189674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection.
    Suzuki F; Toyota J; Ikeda K; Chayama K; Mochida S; Hayashi N; Ishikawa H; Miyagoshi H; Hu W; McPhee F; Hughes EA; Kumada H
    Antivir Ther; 2014; 19(5):491-9. PubMed ID: 24451122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation.
    Hartwell D; Cooper K; Frampton GK; Baxter L; Loveman E
    Health Technol Assess; 2014 Oct; 18(65):i-xxii, 1-202. PubMed ID: 25350588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents.
    Al Ali J; Owayed S; Al-Qabandi W; Husain K; Hasan F
    Ann Hepatol; 2010; 9(2):156-60. PubMed ID: 20526008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration.
    Miyachi N; Zagrijtschuk O; Kang L; Yonezu K; Qin A
    Clin Drug Investig; 2021 Apr; 41(4):391-404. PubMed ID: 33725322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population.
    Jin YJ; Lee JW; Lee JI; Park SH; Park CK; Kim YS; Jeong SH; Kim YS; Kim JH; Hwang SG; Rim KS; Yim HJ; Cheong JY; Cho SW; Lee JS; Park YM; Jang JW; Lee CK; Sohn JH; Yang JM; Han S
    BMC Gastroenterol; 2013 Apr; 13():74. PubMed ID: 23627926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients.
    Bruchfeld A; Lindahl K; Reichard O; Carlsson T; Schvarcz R
    J Viral Hepat; 2006 May; 13(5):316-21. PubMed ID: 16637862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
    Reddy KR; Zeuzem S; Zoulim F; Weiland O; Horban A; Stanciu C; Villamil FG; Andreone P; George J; Dammers E; Fu M; Kurland D; Lenz O; Ouwerkerk-Mahadevan S; Verbinnen T; Scott J; Jessner W
    Lancet Infect Dis; 2015 Jan; 15(1):27-35. PubMed ID: 25482330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.